tiprankstipranks
Advertisement
Advertisement

PRLD Stock Latest News

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
The FlyPrelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
15d ago
PRLD
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
PremiumCompany Announcements
Prelude Therapeutics Launches Phase 1 Trial and Extends Runway
18d ago
8K
PRLD
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
PremiumThe Fly
Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)
18d ago
PRLD
Prelude Therapeutics initiated with a Buy at D. Boral Capital
PremiumThe Fly
Prelude Therapeutics initiated with a Buy at D. Boral Capital
26d ago
PRLD
Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
PremiumCompany Announcements
Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers
28d ago
PRLD
Prelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
PremiumThe FlyPrelude Therapeutics price target raised to $8 from $5 at H.C. Wainwright
1M ago
PRLD
Prelude Therapeutics Prices Public Offering to Extend Runway
Premium
Company Announcements
Prelude Therapeutics Prices Public Offering to Extend Runway
1M ago
8K
PRLD
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
Premium
Company Announcements
Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results
1M ago
8K
PRLD
Prelude Therapeutics presents new preclinical data from PRT13722 study
PremiumThe Fly
Prelude Therapeutics presents new preclinical data from PRT13722 study
1M ago
PRLD
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
PremiumCompany Announcements
Prelude Therapeutics Appoints Veteran Oncologist as New CMO
2M ago
8K
PRLD
Prelude Therapeutics announces Charles Morris as chief medical officer
PremiumThe Fly
Prelude Therapeutics announces Charles Morris as chief medical officer
2M ago
PRLD
Prelude Therapeutics management to meet with Citizens
PremiumThe Fly
Prelude Therapeutics management to meet with Citizens
2M ago
PRLD
Prelude Therapeutics Establishes New ATM Equity Offering Facility
PremiumCompany AnnouncementsPrelude Therapeutics Establishes New ATM Equity Offering Facility
3M ago
8K
PRLD
Prelude Therapeutics price target raised to $6 from $3 at Citizens
Premium
The Fly
Prelude Therapeutics price target raised to $6 from $3 at Citizens
3M ago
PRLD
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
Premium
Company Announcements
Prelude Therapeutics Reports 2025 Results, Highlights JAK2 Program
3M ago
8K
PRLD
Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
PremiumThe Fly
Prelude Therapeutics reports FY25 EPS ($1.29) vs. ($1.68) last year
3M ago
PRLD
Prelude Therapeutics sees cash runway into 2Q27
PremiumThe Fly
Prelude Therapeutics sees cash runway into 2Q27
3M ago
PRLD
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
PremiumCompany Announcements
Prelude Therapeutics Wins FDA IND Clearance for PRT12396
4M ago
8K
PRLD
Prelude receives FDA clearance for investigational IND for PRT12396
PremiumThe Fly
Prelude receives FDA clearance for investigational IND for PRT12396
4M ago
PRLD
Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology
PremiumCompany AnnouncementsPrelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology
4M ago
ONC
PRLD
Prelude Therapeutics unveils strategic investor presentation on pipelines
Premium
Company Announcements
Prelude Therapeutics unveils strategic investor presentation on pipelines
5M ago
8K
PRLD
Prelude Therapeutics files to sell 6.25M shares of common stock for holders
Premium
The Fly
Prelude Therapeutics files to sell 6.25M shares of common stock for holders
6M ago
PRLD

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >